Evidence map›Paper›PMID 38590052›Full record

ArticleHealth policy and planning2024

Health impact and cost-effectiveness of expanding routine immunization coverage in India through Intensified Mission Indradhanush.

Emma Clarke-Deelder, Christian Suharlim, Susmita Chatterjee, Allison Portnoy, Logan Brenzel, Arindam Ray, Jessica L Cohen, Nicolas A Menzies, Stephen C Resch

Abstract read
In one paragraph

Article in Health policy and planning, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Emma Clarke-DeelderDepartment of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States.ORCID 0000-0002-8306-2375
Christian SuharlimCenter for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States.
Susmita ChatterjeeResearch Department, George Institute for Global Health, New Delhi, Delhi 110025, India.ORCID 0000-0002-0937-7205
Allison PortnoyCenter for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States.ORCID 0000-0002-8467-1324
Logan BrenzelBill & Melinda Gates Foundation, Seattle, WA 98109, United States.
Arindam RayBill & Melinda Gates Foundation, New Delhi, Delhi 110067, India.
Jessica L CohenDepartment of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States.
Nicolas A MenziesDepartment of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States.ORCID 0000-0002-2571-016X
Stephen C ReschCenter for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States.

Funding

Bill & Melinda Gates Foundation, Grant OPP1158709
6 · The paper itself

Abstract

Many children do not receive a full schedule of childhood vaccines, yet there is limited evidence on the cost-effectiveness of strategies for improving vaccination coverage. Evidence is even scarcer on the cost-effectiveness of strategies for reaching 'zero-dose children', who have not received any routine vaccines. We evaluated the cost-effectiveness of periodic intensification of routine immunization (PIRI), a widely applied strategy for increasing vaccination coverage. We focused on Intensified Mission Indradhanush (IMI), a large-scale PIRI intervention implemented in India in 2017-2018. In 40 sampled districts, we measured the incremental economic cost of IMI using primary data, and used controlled interrupted time-series regression to estimate the incremental vaccination doses delivered. We estimated deaths and disability-adjusted life years (DALYs) averted using the Lives Saved Tool and reported cost-effectiveness from immunization programme and societal perspectives. We found that, in sampled districts, IMI had an estimated incremental cost of 2021US$13.7 (95% uncertainty interval: 10.6 to 17.4) million from an immunization programme perspective and increased vaccine delivery by an estimated 2.2 (-0.5 to 4.8) million doses over a 12-month period, averting an estimated 1413 (-350 to 3129) deaths. The incremental cost from a programme perspective was $6.21 per dose ($2.80 to dominated), $82.99 per zero-dose child reached ($39.85 to dominated), $327.63 ($147.65 to dominated) per DALY averted, $360.72 ($162.56 to dominated) per life-year saved and $9701.35 ($4372.01 to dominated) per under-5 death averted. At a cost-effectiveness threshold of 1× per-capita GDP per DALY averted, IMI was estimated to be cost-effective with 90% probability. This evidence suggests IMI was both impactful and cost-effective for improving vaccination coverage, though there is a high degree of uncertainty in the results. As vaccination programmes expand coverage, unit costs may increase due to the higher costs of reaching currently unvaccinated children.

Indexed as

Cost-Benefit AnalysisImmunization ProgramsVaccination CoverageChild, PreschoolDisability-Adjusted Life YearsHumansImmunization ScheduleIndiaInfantVaccinationVaccinesVaccinesChild healthhealth economicsvaccines

Identifiers

PMID38590052
PMCPMC11145919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.